Basilea Pharmaceutica AG
BPMUF
$67.75
$6.4110.45%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.70% | 39.13% | 32.76% | 16.62% | -0.44% |
| Total Other Revenue | 313.69% | 184.45% | 91.25% | -31.42% | -72.53% |
| Total Revenue | 62.20% | 45.44% | 35.48% | 12.28% | -9.92% |
| Cost of Revenue | 3.77% | 5.47% | 12.34% | 36.55% | 70.70% |
| Gross Profit | 365.71% | 165.38% | 82.19% | -17.65% | -73.91% |
| SG&A Expenses | 9.13% | 3.07% | 1.81% | 6.54% | 11.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.83% | 4.96% | 9.94% | 29.10% | 54.44% |
| Operating Income | 1,229.08% | 857.45% | 200.80% | -34.24% | -110.75% |
| Income Before Tax | 621.25% | 3,397.36% | 542.33% | -24.56% | -126.54% |
| Income Tax Expenses | 97.48% | -29.58% | -188,415.38% | -598,786.21% | -328,267.39% |
| Earnings from Continuing Operations | 9,803.52% | 1,488.24% | 725.50% | 24.41% | -101.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9,803.52% | 1,488.24% | 725.50% | 24.41% | -101.43% |
| EBIT | 1,229.08% | 857.45% | 200.80% | -34.24% | -110.75% |
| EBITDA | 1,828.44% | 653.79% | 181.13% | -31.71% | -107.10% |
| EPS Basic | 8,633.17% | 1,487.28% | 714.17% | 22.71% | -101.60% |
| Normalized Basic EPS | 614.45% | 3,384.33% | 533.13% | -25.70% | -126.47% |
| EPS Diluted | 2,366.40% | 5,604.67% | 1,249.21% | 23.18% | -105.85% |
| Normalized Diluted EPS | 528.90% | 1,379.84% | 861.09% | -29.48% | -130.23% |
| Average Basic Shares Outstanding | 1.12% | 0.81% | 0.71% | 0.78% | 0.85% |
| Average Diluted Shares Outstanding | 9.44% | 5.56% | 5.59% | 1.86% | -1.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |